JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
144.50
+0.25 (+0.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close144.25
Open143.41
Bid141.56 x 800
Ask144.66 x 800
Day's Range142.48 - 144.51
52 Week Range118.62 - 148.32
Volume6,658,019
Avg. Volume6,623,530
Market Cap387.546B
Beta (3Y Monthly)0.31
PE Ratio (TTM)253.95
EPS (TTM)0.57
Earnings DateJan 22, 2019
Forward Dividend & Yield3.60 (2.47%)
Ex-Dividend Date2018-11-26
1y Target Est147.06
Trade prices are not sourced from all markets
  • MARKETS: Stocks could bounce here, but I'm selling the rally
    Yahoo Finance Video20 hours ago

    MARKETS: Stocks could bounce here, but I'm selling the rally

    Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland.

  • Reuters9 hours ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that centre around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.

  • New jury fails to reach verdict in J&J South Carolina talc cancer trial
    Reuters9 hours ago

    New jury fails to reach verdict in J&J South Carolina talc cancer trial

    The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.

  • Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?
    Zacks20 hours ago

    Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Johnson & Johnson's Up 3% So Far in 2018
    Motley Fool21 hours ago

    Why Johnson & Johnson's Up 3% So Far in 2018

    Here's what's keeping the healthcare giant in check.

  • Should You Be Pleased About The CEO Pay At Johnson & Johnson’s (NYSE:JNJ)
    Simply Wall St.22 hours ago

    Should You Be Pleased About The CEO Pay At Johnson & Johnson’s (NYSE:JNJ)

    Alex Gorsky became the CEO of Johnson & Johnson (NYSE:JNJ) in 2012. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...

  • Why Wall Street Is Still Bullish on Tandem Stock
    Market Realist22 hours ago

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.

  • Jury clears J&J of liability in California talc cancer case
    Reuters2 days ago

    Jury clears J&J of liability in California talc cancer case

    The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.

  • Reuters2 days ago

    Jury clears J&J of liability in California talc cancer case

    The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.

  • AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
    Zacks2 days ago

    AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study

    AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.

  • Tandem Diabetes Care’s Operational Performance
    Market Realist2 days ago

    Tandem Diabetes Care’s Operational Performance

    For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.

  • Why Tandem Should Be on Your Stock Radar
    Market Realist2 days ago

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on pumps’ home screens. This is the only pump capable of remote feature updates on the US market. Tandem also sells disposable products such as cartridges and infusion sets that are used with its pumps and replaced periodically. In August 2018, Tandem began the commercialization of the t:slim X2 in key regions outside the United States.

  • Here’s how to easily reduce your investment risk just at the right time
    MarketWatch2 days ago

    Here’s how to easily reduce your investment risk just at the right time

    Mike Loewengart of E-Trade discusses equal-weighted and bond ETFs, and actively managed funds for diversification.

  • Gauging Analysts’ Views on TransEnterix Stock
    Market Realist2 days ago

    Gauging Analysts’ Views on TransEnterix Stock

    In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.